3SOF

Hi Setravis
Was up checking your post for the morning and seen this one. Looks really good , I liked the chart with PR and recent upgrade and earnings on Nov 13th.
I put limit order in for 4.20 then went to work,,Got in from work and seen that I  got them for 4.11,how about that I think the Fed PR was why ,,Market was down because of it.
Will be planing my trade later tonight since I just got in from work

News out today...


Partnering with General Electric.   

On my watch list NVAX, is brewing to run on the upside and possibly go up to $5.50 resistance....let's see;D

Still waiting for the right entry price......

NVAX breakout now, huge volume came in......

NVAX is holding up so well  & leaving a nice candlesticks from the breakout... 

 

NVAX also down based on the Market conditions (like VPHM)

Yup, fake breakout for NVAX. If you are long in this current market, having a very tight stop is the key to survive in this game.

REPORTS POSITIVE RESULTS FROM PHASE IIa TRIAL:

Novavax, Inc. (NVAX) announced
favorable results from a Phase IIa human clinical trial of its seasonal influenza VLP (trivalent)
vaccine candidate. The vaccine, which does not include an adjuvant, induced robust hemagglutination inhibition (HAI) responses, which have been shown to correlate with protection against seasonal influenza disease. The adverse events that were reported from the trial are similar in type to those reported for other approved influenza vaccines. Adverse events such as fever, chills, joint pain, muscle aches, headaches, and fatigue were reported at a higher frequency among vaccine as compared with placebo recipients. No serious adverse events have been reported to date. Subjects in the study continue to be monitored for safety through 6 months after vaccination.

updated chart scene...
Busted through the 50-day MA with some nice volume.
NVAX working on H1 N1 strain vaccine
INSIDER BUYING

52wk Range: 0.52 - 3.42
Volume: 1,520,395
Avg Vol (3m): 187,363

Technicals
Close Above the 13-day MA
Percentage Gainer

Last Price Quote is:
69.13%above 13-day MA
43.89%above 50-day MA
RS Rating: 17 

Fundamentals
Key Data:
Market Cap (M): $61.97 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/08/2009
Last Analyst Rating: Mkt Outperform

Press Release Source: Novavax, Inc.
NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
On Tuesday April 14, 2009, 8:00 am EDT


H1N1 Virus-like Particle (VLP) Vaccine Candidate Based on the 1918 Spanish Influenza Strain Protected Mice and Ferrets Against the Spanish Flu and Highly Pathogenic H5N1 Bird Flu

ROCKVILLE, Md., April 14 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) today reported preclinical study results showing that an investigational H1N1 virus-like particle (VLP) vaccine based on the 1918 Spanish influenza strain protected against both the Spanish flu and a highly pathogenic H5N1 avian influenza strain. The study, published in the March 25, 2009 online issue of the Journal of Virology, was conducted by scientists from the Centers for Disease Control and Prevention (CDC) in Atlanta, GA and Novavax under a Collaborative Research and Development Agreement.

Novavax scientists designed and produced a recombinant VLP vaccine candidate against the 1918 H1N1 influenza strain. This 1918 influenza strain was responsible for more than 50 million deaths worldwide during the great Spanish flu pandemic. Mice and ferrets were vaccinated with VLPs by one of two routes: either by standard intramuscular injection or by administering a small drop of the VLP vaccine in the nose (intranasal immunization). All of the 1918 VLP-immunized animals were protected when exposed to a lethal dose of the 1918 influenza virus, regardless of the route by which the vaccine was administered. Remarkably, animals immunized by the intranasal route were also protected against a lethal dose of a contemporary, highly pathogenic avian influenza subtype H5N1 virus strain, isolated from a fatal human case in 2004 (A/Vietnam/1203/2004 strain).

The H1N1 VLP vaccine candidate was made up of the hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins from 1918 Spanish influenza virus strains. These proteins, which were produced in insect cells, formed three-dimensional structures that mimic the 1918 pandemic influenza virus but without the genetic material needed for replication. The mechanism of action by which this H1N1 VLP vaccine candidate provided broad cross-protection is under further study, but the scientists described preliminary evidence that antibody cross-reactivity between the HA and possibly NA proteins of the H1N1 and H5N1 influenza were important.

"Unlike other non-live influenza vaccines, the VLPs are uniquely positioned to stimulate immunity through multiple mechanisms," said Dr. Penny Heaton, Chief Medical Officer at Novavax. "First, they contain HA protein that is the same structure as the live virus, which may stimulate HA antibodies of several types that not only prevent the virus from attaching to cells but also prevent the virus from fusing with cells. Second, the VLPs contain NA which may stimulate production of antibody that prevents spread of the virus down the respiratory tract. Finally, the structure of the HA and NA proteins and the way in which they are embedded in lipids on the surface of the VLP may activate the innate immune system providing protection against both the H1N1 and H5N1 strains," said Dr. Heaton.

Although cross protection against influenza strains of the same hemagglutinin or HA type has been achieved through the use of vaccines with adjuvants (e.g., cross-protection against H5N1 A/Vietnam and A/Indonesia strains), protection against strains with different HA types, as shown in this study, has not been reported. Cross-protection against different HA types is highly desirable for pandemic influenza vaccine candidates because it is not possible to predict the strain that may be responsible for the next pandemic with today's technology. A broadly cross-protective vaccine would be ideal for stockpiling in that it could be administered during the first wave of the pandemic while waiting for manufacture of vaccine specific to the pandemic strain.

Dr. Gale Smith, Vice President of Vaccine Development at Novavax, said, "The discovery that a VLP-based influenza vaccine candidate created through cell-based recombinant technology has the potential to protect against diverse strains of influenza has significant implications for both pre-pandemic and pandemic preparedness. A broadly protective vaccine administered prior to and during the first wave of a pandemic could prevent widespread morbidity and mortality from a newly emerged pandemic influenza strain and allow time for the development of strain-specific vaccines."

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary VLP technology. The company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. The Company has VLP vaccine candidates against seasonal influenza and potential pandemic influenza strains in phase II clinical development.

This report describes the second of two preclinical studies of Novavax's investigational H5N1 pandemic influenza vaccine announced this year that have shown different approaches to achieving broad protection against diverse influenza strains. As announced in February, a VLP vaccine with an HA based on several H5 strains showed broad cross-protection against different H5 strains. In the current study, an alternative route of administration resulted in cross-protection against different HA types. Novavax has shown in clinical trials that an H5N1 VLP candidate vaccine given by intramuscular injection is well tolerated and immunogenic in humans. Preclinical research on alternative pandemic influenza VLP vaccine approaches is expected to continue.

Additional information about Novavax is available at www.novavax.com and in the company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical developments, safety, efficacy and potency of our vaccines, and supply availability are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Novavax to secure and maintain relationships with collaborators; risks relating to the early stage of Novavax's product candidates under development; uncertainties relating to commencing clinical trials and their outcome; risks relating to the supply and commercialization, if any, of Novavax's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient enrolment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

  Yummy Yummy  if you brought Friday!
Drugmaker shares rise on swine-flu outbreak.......
Novavax, which owns technology for creating vaccines, was rocketing 

52wk Range: 0.52 - 3.42
Volume: 52,291,341
Avg Vol (3m): 209,637

Technicals
Close Above the 50-day MA
Close Above the 13-day MA
Most Actives
Gap Up
Percentage Gainer

Last Price Quote is:
176.43%above 13-day MA
154.03%above 50-day MA
RS Rating: 15 

Fundamentals
Earnings Expected on May 8

Key Data:
Market Cap (M): $97.77 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/08/2009
Last Analyst Rating: Mkt Outperform

Monday, April 27, 2009, 10:42am EDT  |  Modified: Monday, April 27, 2009, 2:32pm
Swine flu fear lifts Novavax stock
Washington Business Journal

Concern about the outbreak of the swine flu lifted the shares of Novavax Inc. on Monday as investors trolled for firms that might be called on to fight the disease.

Shares of Rockville-based Novavax (NASDAQ: NVAX) rose as much as $2.46, or 173 percent, to $3.88 per share in mid-morning trading.

"By the afternoon, that frenzy wore down to a doubling of Novavax's stock price to $2.83, making the local company the best performer among the new national Swine Flu and Bird Flu Stocks Index compiled by Yahoo Finance".

Last summer, Novavax announced that its experimental vaccine against one strain of avian influenza produced a strong immune response in humans. Novavax says its technology can cut the time it takes to manufacture a vaccine in half which could be seen as important to responding to a rapidly spreading infectious disease such as the swine flu.

Novavax was not the only stock jumping in response to the outbreak.

It took the possible pandemic outbreak of swine flu to spur Novavax to higher highs. The biotech makes a recombinant vaccine technology that could be essential should the flu spread like wildfire and vaccines to fight it become necessary to have in bulk on very short order. Even in the event it doesn't become a worldwide affliction, pharmaceuticals and others will no doubt be taking a closer look at its technology.

Vaccines have become big business since the shortage a few years ago with the government investing billions in stockpiling vaccines and pharmaceutical companies snapping up the vaccine makers. A company like Novavax whose technology can mass produce vaccines quickly would likely command more of a premium than what it trades at currently, even if those share prices have tripled over the past month.

Novavax's on-the-fly technology allows it to maneuver quickly regardless.
This company has mobile lab capabilities, that can make the vaccine on location from the current mutated state, therefore reducing the time it takes to make a vaccine. It also has India's Cipla, as a partner, which makes the generic tamiflu.


52wk Range: 0.52 - 3.88
Volume: 31,278,587
Avg Vol (3m): 1,542,470

Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
120.18%above 13-day MA
177.14%above 50-day MA
RS Rating: 94 

Fundamentals
Earnings Expected on May 8

Key Data:
Market Cap (M): $97.77 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/08/2009
Last Analyst Rating: Mkt Outperform

active in the pre market...